Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rett syndrome (RTT) is a progressive neurodevelopmental disorder caused by mutations in the X-linked gene MECP2. One of the challenges developing therapeutics for RTT has been the lack of a screening system that recapitulates the underlying human disease...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery Platform
Sponsor : The Loulou Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : High-throughput functional screening to develop novel therapies for CDKL5-deficiency disorder using human iPSC-derived cortical organoids.CDKL5 stands for cyclin-dependent kinase-like 5, a protein whose gene is located on the X chromosome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 27, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery Platform
Sponsor : The Loulou Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The collaboration brings together the respective teams’ expertise in drug discovery using human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design to identify potential PD drugs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 29, 2022
Reset All
